Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4287638 | 0.90 | LMNA (0.50) | ALDH1A1KDM4EMEN1KMT2ATSHR | |
| SCHEMBL4285550 | 0.89 | MEN1 (0.40) | ALDH1A1KDM4EMEN1KMT2ALMNA | |
| SCHEMBL4285501 | 0.88 | RAB9A (0.41) | ALDH1A1KDM4EMEN1KMT2AGAA | |
| SCHEMBL4281106 | 0.88 | BTK (0.39) | ALDH1A1KDM4ELMNAGAA | |
| SCHEMBL4287941 | 0.83 | KDM4E (0.47) | ALDH1A1KDM4EMEN1KMT2ATSHR | |
| SCHEMBL4297009 | 0.83 | KDM4E (0.47) | ALDH1A1KDM4EMEN1KMT2AHTT | |
| SCHEMBL4294041 | 0.83 | HCRTR1 (0.40) | ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL4284656 | 0.83 | FFAR1 (0.42) | ALDH1A1KDM4EMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4282070 | 0.81 | NPC1 (0.48) | ALDH1A1KDM4EMEN1KMT2ALMNA | |
| SCHEMBL4285755 | 0.81 | KDM4E (0.51) | MAPK1ALDH1A1KDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156612-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | MAPK1 422/4885ALDH1A1 388/4885HIF1A 1683/4885 |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | MAPK1 422/4885ALDH1A1 388/4885HIF1A 1683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.